Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
about
Cerebrolysin for vascular dementiaCerebrolysin for vascular dementiaHuperzine A for vascular dementiaHuperzine A for vascular dementiaCognitive impairment and stroke in elderly patientsDementiaDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsIs drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centresWeight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.Dementia.The effect of an interactive cycling training on cognitive functioning in older adults with mild dementia: study protocol for a randomized controlled trial.Binswanger's disease: toward a diagnosis agreement and therapeutic approachRisk of Long-Term Care Dependence for Dementia Patients is Associated with Type of Physician: An Analysis of German Health Claims Data for the Years 2006 to 2010.Post-stroke dementia - a comprehensive review.Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1Packages of care for dementia in low- and middle-income countries.Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.Multi-Infarct Dementia: A Historical Perspective.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.The science of stroke: mechanisms in search of treatments.Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)The Role of Capillaries in the Lesser Ailments of Old Age and in Alzheimer's Disease and Vascular Dementia: The Potential of Pro-Therapeutic Angiogenesis.Age-related white matter changesVascular cognitive impairment: disease mechanisms and therapeutic implications.Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy.Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.Medial temporal atrophy and memory dysfunction in poststroke cognitive impairment-no dementia.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia.Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.NMDA receptors in clinical neurology: excitatory times ahead.Escitalopram and enhancement of cognitive recovery following stroke.Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementiaExcess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: A double-blind placebo-controlled clinical trial (Phase IIIb pilot study).Vascular disease and cognitive impairment.Vascular factors and prevention of dementia.
P2860
Q24201712-687B2D46-3393-4383-A3EB-67701765F1D1Q24235891-0DAC4730-D7B8-476A-8831-45FE1344D992Q24241186-4BACE69C-D308-49EE-B8A5-A3082162C244Q24242597-4B9755F0-9BA4-4EE0-9642-304723774E83Q26749183-4E5727ED-CD52-4875-82F2-D35E75FE2D2EQ26860881-62B6CD86-1A5A-4224-ABEB-EDDEFAB1267FQ28305100-725B30D2-74CB-449D-B04B-4BB9D9DF1B28Q28486268-BD570366-F656-42F7-AC2A-AF52E004F8F4Q30234535-9280B5B3-1537-44C2-85CE-5882CD8EA2D7Q30404451-08178969-D6F2-460B-8F21-30584C3EFC05Q30842623-5E7ED0EE-57AE-4412-AAAB-D5C4E70DE012Q30848732-5D9C68D4-0A6E-4A4C-83FF-97007B240A0AQ30996681-013B0E66-417C-495E-88FC-8AC3B287407FQ31155081-3B67FFF3-D57C-45E1-BB2A-1B9D2C30AB6BQ31155412-9F28B381-1543-4EEF-B9B3-3A1D5F6BA3F4Q33165693-48800EB4-3134-4C5D-B02E-F54502A838BEQ33362745-A9CA158D-2CA5-4673-AFB4-70A1A5B78C89Q33514859-F0A745A0-0D27-43C1-B44A-EDEC3B600B57Q33552656-4834AD8E-0109-4DCC-9985-46C710179D32Q33801608-E4D99346-501C-4632-9E52-5EF8008A35B4Q33967781-3BD18B34-6306-48E4-86FA-E18AD71DEE54Q34212337-D9C83BAB-ED8C-4728-9C0B-849E90392033Q34403971-C1209A74-3905-4779-8792-6FE7C6B79DF6Q34533560-D6847F49-064C-4B0B-86BE-AD551DB2007CQ35184834-CD92F277-9A81-48B7-9072-BE0C72CE5534Q35197111-92A17328-428B-4272-9F42-4EDB1DEA566EQ35622561-932013A5-8C2D-4B5A-9951-FC17A9D98DF9Q35765716-A0C8F614-FF36-490A-8DFF-BA12198F4861Q35886375-E9842ED7-5709-4ADF-A476-6C6DEA5DB823Q36283014-2492ACE9-FA04-4112-B305-797C42C5B062Q36291488-4F1B099D-E451-4161-AD25-6AA3EA180E3FQ36297147-8246BC63-4893-4ADC-B586-3FC008AFA8FFQ36660216-07C9A879-E4B5-4A5A-9E59-2483CE8B0FDAQ37032754-819918AD-F6E7-404B-971D-3BE5AF842A55Q37063986-82336C19-BBAB-479C-A63E-3FE422B570A0Q37089395-C6425AC0-C07A-4D11-8352-AD6E3DFD317CQ37131376-89295E3A-9A0F-487B-9F6F-ADDC32FD2923Q37167364-774051B5-728F-4DCE-8F55-F0CD9C18F087Q37229301-2FFE43A6-2686-4A34-A735-934E3E096A19Q37299896-D2F22FE9-C667-4898-9C90-FDBCD87AA857
P2860
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Efficacy and adverse effects o ...... randomised controlled trials.
@ast
Efficacy and adverse effects o ...... randomised controlled trials.
@en
Efficacy and adverse effects o ...... randomised controlled trials.
@nl
type
label
Efficacy and adverse effects o ...... randomised controlled trials.
@ast
Efficacy and adverse effects o ...... randomised controlled trials.
@en
Efficacy and adverse effects o ...... randomised controlled trials.
@nl
prefLabel
Efficacy and adverse effects o ...... randomised controlled trials.
@ast
Efficacy and adverse effects o ...... randomised controlled trials.
@en
Efficacy and adverse effects o ...... randomised controlled trials.
@nl
P1433
P1476
Efficacy and adverse effects o ...... randomised controlled trials.
@en
P2093
Harish Kavirajan
Lon S Schneider
P304
P356
10.1016/S1474-4422(07)70195-3
P577
2007-09-01T00:00:00Z